Abbott, Rubicon in MethylPlex pact:
This article was originally published in Clinica
Rubicon Genomics is to team up with Abbott Molecular to develop cancer tests using Rubicon's MethylPlex methylation detection technology. Under the multi-year research and option agreement, the two companies will focus primarily on noninvasive detection of prostate and bladder cancer. According to Ann Arbor, Michigan-based Rubicon, its MethylPlex technology offers a highly sensitive method for detecting the patterns of abnormal DNA methylation arising in serum and urine during tumour formation and progression.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.